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Background: The impact of neoadjuvant chemotherapy (CT) and radiotherapy (RT) on overall
survival (OS) has been controversial. Some studies have pointed to an improvement in OS
and disease-free survival (DFS) in patients with pathologic complete response (pCR).
Aim: To evaluate the therapeutic response and impact on survival of preoperative RT, alone
or combined with CT, in patients with locally advanced rectal cancer (LARC).
Materials and methods: A set of 132 patients with LARC were treated preoperatively.
GROUP 1: RT alone, 19 patients. GROUP 2: RT and concomitant oral CT (Capecitabine or
UFT+ leucovorin), 68 patients. GROUP 3: RT and concomitant CT with 5-FU in continuous
infusion, 45 patients. 58.2% of patients were submitted to adjuvant CT.
Results: GROUP 1: no pCR, tumoral downstaging was 26.7%. GROUP 2: pCR in 16.9%; tumoral
downstaging was 47.7%. GROUP 3: pCR in 11.9%; tumor downstaging was 52.4%. The loco-
regional control (LRC) was 95%. The 5-year OS (p=0.038) and DFS (p=0.05) were signiﬁcantly
superior in patients treatedwith CT+RT. Patientswith pCR had a signiﬁcant increase onDFS
(p=0.019). Patients cT3–4 that had a tumoral downstaging to ypT0–2, showed an increase
on DFS, OS and LRC.Conclusions: CT combined with RT has increased tumoral response and survival rate. Nodal
downstaging and pCR were higher in the GROUP 2. The 5-year OS and DFS were signiﬁcantly
superior in CT+RT arms. Patients with pathologic response showed a better DFS. Adjuvant
CT had no impact on LRC, DFS nor on OS.
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the rate of local relapse and prolong survival in patients
whose tumors extend into the perirectal fat (T3) or who
have involvement of mesorectal or pelvic lymph nodes
(N1–3).1
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Preoperative chemoradiotherapy (CT+RT) offers some the-
oretical advantages over adjuvant therapy for patients with
a tumor of the middle to lower rectum2: (i) micrometastases
are treated early in the course of the disease; (ii) the risk of
tumor seeding during surgery is reduced; (iii) RT toxicity is
also reduced; (iv) the efﬁcacy of CT and RT is higher in a tumor
with an intact vasculature; (v) if the tumor shrinks, a sphinc-
ter preserving procedure can be performed. Nevertheless, this
treatment also has some drawbacks: (i) deﬁnitive therapy is
delayed,whichmayallow the growth anddissemination of the
tumor; (ii) as preoperative staging is not very precise, patients
on early stages (T1–2N0) of the disease, who do not need this
therapy because of their very low risk of relapse, would be
overtreated.
After the randomised trial CAO/ARO/AIO,3 neoadjuvant
CT+RT became the standard treatment, since the 5-year
local recurrence rate is reduced, adherence is better and
it has fewer acute and long-term toxic effects than post-
operative CT+RT. Neoadjuvant use of CT and RT allow a
higher rate of resectability associated to a tumor and nodal
downstaging.4
Concomitant neoadjuvant 5-FU CT+RT provides a pCR
in 8–27% of the cases and is associated to an increased
local control.2–14 The single randomized trial that compared
preoperative vs. postoperative CT+RT, concluded that there
was a higher tumoral downstaging (6% vs. 13%, p=0.006) and
a decrease on local recurrence with preoperative CT+RT.3
Theoretically, oral ﬂuoropyrimidines are suitable to replace
protracted infusion of 5-FU and avoid complicated procedures.
The impact of neoadjuvant CT+RT on survival has been
controversial. Some studies have pointed to an improve-
ment in overall survival (OS) and disease-free survival (DFS)
in patients with pathological response after neoadjuvant
therapy.9,15,16Since the standard schedule of preoperative CT+RT for
rectal cancer remains to be established, and due to the con-
venience of oral prodrugs of 5-FU, we have evaluated the
therapeutic response to UFT and leucovorin (LV), capecitabine
Table 1 – Patients’ characteristics.
Patients’ characteristics GROUP 1 (n=
RT alone
Age (years) Min–Max 51–83
Median 74
Sex Male 13 (68.4%)
Female 6 (31.6%)
Karnofsky 100% 1 (5.3%)
90% 8 (42.1%)
80% 10 (52.6%)
Distance to anal
margin
0–5 cm 12 (63.2%)
6–11 cm 7 (36.8%)
Imaging staging (CT/MRI) 52.6%/42.1%
Clinical staging cT2 –
cT3 16 (84.2%)
cT4 3 (15.8%)
cN0 4 (21.1%)
cN+ 15 (78.9%)diotherapy 1 5 ( 2 0 1 0 ) 51–59
and 5-FU combined with preoperative RT in patients with
stage II–III rectal cancer. Toxicity and survival were also anal-
ysed for those groups of patients, as well as the relationship
between pathologic response and survival.
2. Methods
2.1. Patients
We analysed prospectively 132 patients with locally advanced
rectal cancer (LARC) treated with neoadjuvant RT from
November 2002 to March 2008. Patients were divided into 3
groups. GROUP 1: consisting of 19 patients who were treated
with RT alone; most of these patients were treated in the
beginning of the study, before well deﬁned criteria for using
CT+RT were established, whereas others were submitted
to this therapy because of associated co-morbidities and
advanced age. GROUP 2: consisting of 68 patients who were
treated with RT and concomitant oral CT. GROUP 3: consist-
ing of 45 patients, submitted to RT and concomitant CT with
continuous infusion of 5-FU. Patients’ characteristics as rep-
resented by particular groups are described in Table 1.
2.2. Neoadjuvant radiotherapy
The patient prone position was recommended, and a belly
board immobilization device was used. A pelvic CT in the
treatment position was performed on all patients, from L5–S1
to 2 cm distal to the anus. All patients underwent three-
dimensional treatment planning. CT was used to deﬁne gross
tumor volume (GTV). Clinical target volume (CTV) included the
GTV+2cm in all directions, perirectal, internal iliac and pre-
sacral nodes up to the promontory; for T4 (seminal vesicles,
prostate, vagina or uterus involvement) external iliac nodes
were also included; the inguinal areas were irradiated in those
patients who had invasion of the anal canal.17,18
19) GROUP 2 (n=68)
RT+oral CT
GROUP 3 (n=45)
RT+ infusional CT
35–81 20–77
64 61
46 (67.6%) 25 (55.6%)
22 (32.4%) 20 (44.4%)
40 (58.8%) 30 (66.7%)
24 (35.3%) 14 (31.1%)
4 (5.9%) 1 (2.2%)
38 (55.9%) 22 (48.9%)
30 (44.1%) 23 (51.1%)
19.1%/79.4% 0%/100%
7 (10.3%) 5 (11.1%)
57 (83.8%) 28 (62.2%)
4 (5.9%) 12 (26.7%)
9 (13.2%) –
59 (86.8%) 45 (100%)
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The planning target volume (PTV) was deﬁned as
TV+1cm margin. The treatment was delivered through
hree to four ﬁelds via the isocenter technique, shaped with
ultileaf collimator, and high-energy photons of 18MV. The
otal dose administered was 50.4Gy with conventional frac-
ionation of 1.8Gy/d, ﬁve times per week. The prescribed dose
as speciﬁed at the International Commission on Radiation
nits and Measurements point and isodose distribution to the
TV (95–107%).
.3. Neoadjuvant chemotherapy
ROUP2was treatedwith oral CT concomitant to RT, including
apecitabine or UFT. The Capecitabine group received an oral
25mg/m2 dose twice daily for the duration of RT (49 patients).
he UFT group received a dose of 300mg/m2/d of UFT together
ith LV 90mg/d (19 patients), in three fractions/d, 5 days/week
Monday to Friday, with the weekend as a rest period).
GROUP 3 was treated with RT concomitant to infusional
T and 5-FU was administered at a dose of 225mg/m2/d in a
ontinuous infusion, 5 days/week, from Monday to Friday.
.4. Surgery
atients were scheduled for surgery between the sixth and
ighth week following the conclusion of the neoadjuvant ther-
py and were treated with total mesorectum excision.
.5. Toxicity assessment
oxicity was evaluated weekly in each patient using Common
erminology Criteria for Adverse Events vs. 3.0 (CTCAE).19 A
omplete blood count and biochemical tests were obtained
eekly.
.6. Deﬁnition of response
valuation of response to preoperative treatment was deﬁned
athologically. Resected tumors were classiﬁed pathologically
ccording to the TNM staging system, version 6.20 Tumor
ownstaging was deﬁned as postoperative ypT stage lower
han preradiotherapy clinical cT stage. Nodal downstaging
as deﬁned as postoperative ypN stage lower than preradio-
herapy clinical cN stage. Loco-regional response was deﬁned
s a downstaging from cTN to pTN. A pathologic complete
esponse (pCR) was considered to occur when there were no
alignant cells observed.
.7. Adjuvant treatment
fter surgery, adjuvant CT was given to patients who were
onsidered by the treating physician to potentially beneﬁt
rom the postoperative therapy. The protocols of adjuvant
T used were FOLFOX (28.2%), CAPOX (11.3%), De Gramont
16.9%), Capecitabine (28.2%), UFT (11.3%) or others (4.1%).
.8. Follow-upollowing the conclusion of treatment, patients had outpa-
ient clinic appointments every 3 months for the ﬁrst 2 years,
nd then every 6 months.iotherapy 1 5 ( 2 0 1 0 ) 51–59 53
2.9. Patterns-of-failure analysis and survival
Loco-regional failure was deﬁned as a relapse in the pelvis
(tumor bed, pelvic nodes, anastomosis, or perineal scar). Fail-
ure at distance was deﬁned as relapse in any other site. OS,
DFS, and loco-regional control (LRC) were calculated from the
date of beginning of treatment. For the calculation of OS, only
deaths related to the disease were scored as events.
2.10. Statistical considerations
Statistical analyses were performed using the SPSS 16.0 sta-
tistical package. The p-value was calculated by the chi-square
test to compare variables. OS, DFS and LRC probabilities were
calculated by the Kaplan–Meier method, and differences were
evaluated by the log-rank test. A two-sided p-value of <0.05
was considered statistically signiﬁcant.
3. Results
3.1. Toxicity and treatment adherence
3.1.1. Preoperative treatment
Overall, preoperative therapies were well tolerated and the
most commonly reported events are shown in Table 2. In the
RT arm, the rate of acute toxicity was 68.4%, but there were
no grade 3–4 acute side effects. Group 2 presented acute tox-
icity in 80.9% of patients, of whom only 7 (10.3%) were grade
3–4. Group 3 showed an acute toxicity in 65.9% of patients, of
whom5 (11.4%)were grade 3–4.Onepatienthadnot completed
treatment due to allergic reaction to 5-FU and was excluded.
There were no signiﬁcant differences (p=0.245) on toxicity
of neoadjuvant therapy among the 3 groups.
3.1.2. At surgery
The median time interval between the end of RT and surgery
was 6–7 weeks. A complete resection was done in most
patients undergoing CT+RT (GROUP 2: 85.3%; GROUP 3: 88.9%),
whereas in the RT group the rate was 63.1%. It should be noted
that the group treated with RT alone was the one which had a
higher percentage of unresectable disease (21.1%). One patient
was not operated due to disease progression and another
because of intercurrent illness (Table 3). The main postoper-
ative complications were surgical wound infections, ﬁstula,
suture dehiscence and sub-occlusive disease (Table 4). These
complications did not increase with the addition of CT to RT
(p=1.0). Two patients died postoperatively due to pulmonary
thromboembolism.
3.1.3. Postoperative treatment
Of the 122 patients who were submitted to radical surgery
and who were candidates for adjuvant CT, only 58.2% (71/122)
received the proposed treatment. The respective acute toxici-
ties (67.6% of patients) are described in Table 5.The majority of the 51 patients who did not receive
adjuvant CT were affected with postoperative complications
(52.9%). The reasons why the latter did not undergo adjuvant
CT are described in Table 6.
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Table 2 – Incidence of acute toxicity. CTCAE (v. 3.0).
Acute toxicity (%) GROUP 1 GROUP 2 GROUP 3
Grade 1–2 Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3
Diarrhea 31.6 25.0 7.4 1.5 24.4 6.7
Vomiting 5.9 4.4 2.2
Radiodermitis 36.8 50.0 4.4 53.3
Hand-Foot Synd. 7.4 4.4
Anemia 15.8 7.4 2.2 2.2
Leukopenia 4.4
Thrombocytopenia 2.9
Elevated transaminases 4.4
Elevated creatinine 2.2
Nausea 1.5
Urinary 1.5
Table 3 – Median time surgery-RT and surgical status.
GROUP 1 (N=19) RT alone GROUP 2 (N=68) RT+oral CT GROUP 3 (N=44) RT+ infusional CT
Timing to surgery (median) 7 weeks 6 weeks 6.5 weeks
Surgical resection
R0 12 (63.1%) 58 (85.3%) 40 (90.9%)
R1 3 (15.8%) 7 (10.3%) 2 (4.5%)
Unresectable 4 (21.1%) 2 (2.9%) 1 (2.2%)
Non-operated – 1 (1.5%) 1 (2.2%)
Table 4 – Incidence of postoperative complications.
Postoperative complications GROUP 1 (N=15) RT alone GROUP 2 (N=65) RT+oral CT GROUP 3 (N=42) RT+ infusional CT
Suture dehiscence 1 (5.9%)
Sub-occlusion/occlusion 3 (20%)
Fistula –
Infection 2 (11.7%)
Table 5 – Adjuvant CT acute toxicities incidence.
CTCAE (v. 3.0) Adjuvant CT toxicities
Grade 1–2 Grade 3–4
Diarrhea – 3 (4.2%)
Vomiting 2 (2.8%) –
Anorexia 1 (1.4%) –
Hand–foot synd. 2 (2.8%) 5 (7%)
Anemia 31 (43.7%) –
Asthenia 2 (2.8%) –
Thrombocytopenia 18 (25.3%) –
Paresthesia 19 (26.8%) 1 (1.4%)
Weight Loss 1 (1.4%) –
Nausea 4 (5.6%) –
Neutropenia 15 (21.1%) 4 (5.6%)
Table 6 – Reasons for non-prescription of adjuvant CT.
Reasons for non-prescription
of adjuvant CT
Number of patients (%)
Postoperative complications 27 (52.9%)
Complete pathologic
response+ypT2N0M0
8 (15.7%)
Not sent to oncology department 4 (7.8%)
Poor performance status (≥3) 3 (5.9%)
Progression of the disease 2 (3.9%)
Deceased 2 (3.9%)
Other 4 (8%)7 (10.8%) 2 (4.8%)
5 (7.7%) 1 (2.4%)
4 (6.1%) 4 (9.5%)
11 (16.2%) 3 (7.1%)
3.2. Treatment response
Although tumor downstaging was higher in patients treated
with preoperative CT+RT, no statistical signiﬁcance (p=0.224)
was found (Fig. 1). Nodal downstaging (p=0.008) and loco-
regional response (p=0.009) were higher in patients treated
with oral CT+RT (Figs. 2 and 3). There was no pCR in GROUP
1. In turn, in GROUP 2 the rate of pCR was 16.9% and 11.9% in
GROUP 3 (p=0.207) (Fig. 4).
Fig. 1 – Tumor downstaging.
Fig. 2 – Nodal downstaging.
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4ig. 3 – Loco-regional response to neoadjuvant therapy.
The median follow-up was 40 months (4–79 months) and
ne patient was lost in the follow-up.
The LRC was of 95% (115/121). In those patients who had
oco-regional recurrence, 3 had undergone anR1 resection and
also haddistant recurrence. The global 3- and 5-yearDFSwas
Figs. 5 and 6 – OS and DFS of patients treated wi
Figs. 7 and 8 – pCR impFig. 4 – Pathologic complete response rate.
75%and68%, respectively. The global 3- and 5-yearOSwas 88%
and 80%, respectively.Comparing the patients that underwent neoadjuvant
CT+RT to those who were only treated with preoperative
RT (Figs. 5 and 6), we veriﬁed that the former had better OS
(p=0.038) and DFS (p=0.05).
th neoadjuvant RT vs. neoadjuvant CT+RT.
act on OS and DFS.
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Figs. 9–11 – Impact of pathologic downsta
Fig. 12 – Impact of adjuvant CT on DFS in patients
submitted to neoadjuvant CT+RT.ging to ypT0–2 on LRC, DFS and OS.
Considering only the patients treated with neoadjuvant
CT+RT, those with pCR had a better 5-year OS (100% vs.
81%, p=0.111) and DFS (100% vs. 62%, p=0.023) (Figs. 7
and 8).
If we only consider the patients clinically staged as cT3–4
that had undergone neoadjuvant CT+RT, we noticed a signiﬁ-
cantly better 5-year LRC (100% vs. 89%, p=0.027), DFS (88% vs.
43%, p=0.003) and OS (89% vs. 77%, p=0.048) in those patients
who had downstaging to ypT0–2 (Figs. 9–11).
The addition of adjuvant CT to the patients scheduled
for neoadjuvant CT+RT did not bring a beneﬁt on 5-year
LRC (95% vs. 95%, p=0.828), on 5-year DFS (60% vs. 78%,
p=0.654) (Fig. 12) nor on 5-year OS (75% vs. 84%, p=0.932).
For the patients who had pathologic downstaging to ypT0–2,
the 5-year DFS was similar for those who were submitted or
not to adjuvant CT (90% vs. 93%, respectively; p=0.578). In
those patients who had no pathologic downstaging (ypT3–4)
and were/were not treated with adjuvant CT, there was
also no evidence of beneﬁt on the 5-year DFS (32% vs. 65%;
p=0.773).
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Table 7 – Neoadjuvant chemoradiotherapy results (2–14). C: capecitabine; L: leucovorin.
Authors No. RT CT Downstaging T (%) Downstaging N (%) pCR (%)
De Paoli (5) 53 50.4 C 57 78 24
Krishnan (6) 54 52.5 C 51 52 18
Kim (7) 95 50.4 C 57 69 12
De la Torre (8) 77 45–50.4 5-FU 43.3 25 13.2
78 UFT,L 59.2 23.7 13.2
Feliu (2) 41 50.4 UFT,L 61 – 15
Janjan (9) 117 45 5-FU 62 – 27
NSABP R-03 (10) 58 50.4 5-FU,L – – 8
Sauer (3) 421 50.4 5-FU – – 8
Kim (11) 145 50.4 5-FU,L – – 11.3
133 C – – 16.1
Crane (12) 207 45 5-FU 62 – 23
196 – 42 – 5
Gérard FFCD 9203 (13) 375 45 5-FU,L – – 11.4
367 – – – 3.6
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. Discussion and conclusions
reoperative CT+RT can lead to tumor downstaging and
mproves ressectability in LARC.21,22 Continuous i.v. 5-FU infu-
ion is superior to 5-FU bolus in terms of tumor response,
nd it is associated to a slight increase in OS and LRC in
dvanced colorectal cancer.23,24 Although continuous i.v. infu-
ion has the biologic advantage of prolonging the exposure
f cells to 5-FU and improving antitumor activity, its disad-
antages include the requirement of a central venous access
ith potential complications, such as bleeding, thrombosis
nd pneumothorax.25 Oral CT mimics the pharmacokinetics
f continuous 5-FU infusion while avoiding technical barriers
f i.v. infusion and being more convenience. Oral ﬂuoropy-
imidines, UFT and Capecitabine, constitute an attractive
lternative.
Neoadjuvant pelvic RT combined with CT should be
egarded as standard treatment for stage II and III rectal can-
er. Although there is an increase in acute toxicity, it did not
lter the compliance to treatment.26
The most commonly reported early endpoint is the rate
f pCR. It appears to be associated in some non-randomized
tudieswith improvement in DFS.9,27 It has been shown in one
andomized trial that time interval between RT and surgery
nﬂuences the degree of downstaging, with 10% of patients
perated within 2 weeks after RT experiencing pathological
ownstaging compared to 26% of patients operated in 6–8
eeks after RT (p=0.005).28 Many studies have shown that
eoadjuvant CT+RT signiﬁcantly increases the rate of pCR,
s well as nodal and tumor downstaging (Table 7).
In our study we veriﬁed that the combination of CT to
T signiﬁcantly increased the tumor response, especially
he nodal downstaging, at the expense of a higher but
anageable toxicity. It also allowed a higher complete surgi-
al resection without increasing postoperative complications
ate.– – 13.7
– – 5.3
54 – 15
Tumor downstaging was superior in patients treated with
CT+RT (GROUP 2: 47.7%; GROUP 3: 52.4%) than in patients of
the RT arm (26.7%) (p=0.224). Nodal downstaging was signiﬁ-
cantly better (p=0.008) in GROUP 2 (82.1% vs. 54.5% and 54.8%).
The neoadjuvant CT+RT groups had better pCR (GROUP 2:
16.9%; GROUP 3: 11.9%) compared to the RT arm (0%) (p=0.207).
All these results are comparable to those described in several
other studies.2–14
We registered a LRC of 95%. The global 3- and 5-year DFS
was 75% and 68%, respectively. The global 3- and 5-year OS
was 88% and 80%, respectively.
Both 5-year OS (84% vs. 59%, p=0.038) and DFS (69% vs.
55%, p=0.05) were signiﬁcantly higher in patients treated with
neoadjuvant CT+RT than in the RT group.
A recent randomized phase III study compared preoper-
ative RT with CT+RT in non-resectable rectal cancer and
veriﬁed that the patients treated with CT+RT had better pCR
(16% vs. 7%, p=0.04), local control (82% vs. 67%, p=0.03), time
to treatment failure (63% vs. 44%, p=0.03), cancer-speciﬁc sur-
vival (72% vs. 55%, p=0.02) and OS (66% vs. 53%, p=0.09).29
Comparing our resultswith the single randomized phase III
trial8 that compared 5-FUvs. oral ﬂuoropyrimidine,wenoticed
that 3-year OS (87% vs. 74%) and LRC (92.5% vs. 91.1%) were
similar to those of the CT+RT group in our study (90% and
77%, respectively). Sauer et al. conducted a randomized trial
comparing preoperative vs. postoperative CT+RT and in the
preoperative group 5-year OS was 76% and LRC 94%.3
Carlos Fernandez-Martos et al. studied preoperative
CT+RT with UFT and the actuarial rate of 3-year DFS was
72% and OS was 75%. DFS was 92% for downstaging patients
and 51% for patients who had not responded (p<0.00001). OS
was signiﬁcantly higher (p=0.002) for patients with downstag-
ing following preoperative treatment than for patients who
had not responded.14 Another study15 also veriﬁed that pCR
or intermediate response was related to an improved DFS
after CT+RT. Julio Garcia-Aguilar et al. analysed 168 patients
treated with CT+RT and had a 5-year LRC of 95%, OS of
nd ra
r58 reports of practical oncology a
68% and a DFS of 95.2% in patients who had pCR and 55.4%
in patients without pCR. Their study suggested that a pCR
to CT+RT is a favorable prognostic factor in patients with
LARC.16
The Gastro-Intestinal Working Group of the Italian Asso-
ciation of Radiation Oncology analysed retrospectively 566
patients with LARC achieving pCR after neoadjuvant therapy
and they veriﬁed that this favorable group of patients had a
very low rate of local recurrence (1.2%) and a favorable clinical
outcome independent of the neoadjuvant CT schedule used,
achieving a 5-year DFS of 84.7% and 5-year OS of 91.6%. In
such a group of patients, the use of postoperative CT could be
very debatable. Conversely, the subset of patients older than
60 years, with cStage III and treated with a radiation dose of
45Gy or less experienced a relatively worse prognosis, even
after achieving ypCR. The prognosis of the high-risk group
of patients compares with the outcome of a non-selected
population.30
In our study, considering only the patients treated with
neoadjuvant CT+RT, those with pCR also had a better 5-
year DFS (100% vs. 62%, p=0.023) and OS (100% vs. 81%,
p=0.111).Whenwe consider only the patients clinically staged
as cT3–4 who underwent neoadjuvant CT+RT, we also veri-
ﬁed a signiﬁcantly better 5-year LRC (p=0.027), DFS (p=0.003)
and OS (p=0.048) in those patients who had downstaging
to ypT0–2.
On the other hand, Pucciarelli et al. have not found
statistically signiﬁcant differences for DFS and OS on
comparing the actuarial survival curves of patients with
different tumor responses to preoperative treatment,
whether evaluated as tumor regression grade or as pTNM
stage.31
There are still insufﬁcient data on adjuvant postoperative
chemotherapy after preoperative treatment with chemora-
diation to come to any conclusions about its use.32,33 A
recent study showed that adjuvant CT was still of border-
line signiﬁcance (worse for adjuvant CT).30 In the EORTC
22921 trial postoperative chemotherapy had a non-signiﬁcant
inﬂuence on local relapse and relapse free and overall
survival. Exploratory subgroup analyses suggest that only
good-prognosis patients with downstaging of cT3–4 to ypT0–2
beneﬁt from adjuvant CT, with better DFS and OS.34 They con-
cluded it was not because tumor downstaging was achieved
that those patients also beneﬁted from further CT, but rather
that the same patients who achieved downstaging had a dis-
ease which was responsive to both the preoperative and the
adjuvant treatment. These data support those shown in other
trials, as the QUASAR trial, that had a signiﬁcant beneﬁt on
survival of 3–6%.35
In our study the addition of adjuvant CT to the patients
scheduled for neoadjuvant CT+RT did not bring a beneﬁt on
5-year LRC (95% vs. 95%, p=0.828), on 5-year DFS (p=0.654) nor
on 5-year OS (p=0.932). However, in the subgroup analyses our
results disagree from those observed in the EORTC trial. If we
only consider those patients who had pathologic downstaging
to ypT0–2, the 5-year DFS was identical for those who were
submitted to adjuvant CT and those were not (p=0.578). For
the patients who had no pathologic downstaging (ypT3–4), the
administration of adjuvant CT did not have any beneﬁt on 5-
year DFS (p=0.773).diotherapy 1 5 ( 2 0 1 0 ) 51–59
Although the results of our study are very promising, we
need to take into account that this study is not a randomized
trial and it might have some bias in the patients’ treatment
modality distribution thatmight inﬂuence someof the results.
We hope soon to increase the total number of patients so we
could be able to conﬁrm the impact of the pathologic response
and adjuvant CT on OS and DFS.
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